Peringatan Keamanan

Overdose studies have not been performed but major cases of hypersensitivity have been reported.L2326

Patent Blue

DB13967

small molecule approved

Deskripsi

Patent blue is aniline dye and it is one of the most common dyes used.A32573 It is a sodium or calcium salt of diethylammonium hydroxide inner salt.A32574 It has the chemical designation of (4-(alpha-(p-(diethylamino)phenyl)-2,4-disulfobenzylidene)-2,5-cyclohexadiene-1-ylidene)diethylammonium hydroxide. Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979.L1113 The isomer isosulphan is used in the United States for the same indications than patent blue.A32574

Struktur Molekul 2D

Berat 561.69
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The elimination half-life is of about 24-48 hours.[L2326]
Volume Distribusi This pharmacokinetic parameter has not been studied.
Klirens (Clearance) This pharmacokinetic property has nos been fully studied.

Absorpsi

Patent blue is selectively absorbed in the lymphatics.A32574 When administered orally, patent blue has a very low absorption and limited systemic availability.L2331

Metabolisme

In vitro studies have shown that patent blue is not metabolized.L2331

Rute Eliminasi

Patent blue is excreted into the urine and bile.A32574The excretion is more significant in the urine which after the administration of patent blue intravenously can even change to a blue coloration.L2326 When administered orally, patent blue is excreted unchanged in feces.L2331

Interaksi Obat

958 Data
Esmolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Esmolol.
Betaxolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Betaxolol.
Metoprolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Metoprolol.
Atenolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Atenolol.
Timolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Timolol.
Sotalol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Sotalol.
Propranolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Propranolol.
Labetalol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Labetalol.
Bisoprolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Bisoprolol.
Alprenolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Alprenolol.
Pindolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Pindolol.
Carvedilol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Carvedilol.
Propafenone The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Propafenone.
Acebutolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Acebutolol.
Nadolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Nadolol.
Bevantolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Bevantolol.
Practolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Practolol.
Penbutolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Penbutolol.
Oxprenolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Oxprenolol.
Dexpropranolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Dexpropranolol.
Celiprolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Celiprolol.
Nebivolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Nebivolol.
Bufuralol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Bufuralol.
Bopindolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Bopindolol.
Bupranolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Bupranolol.
Indenolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Indenolol.
Arotinolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Arotinolol.
Levobetaxolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Levobetaxolol.
Talinolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Talinolol.
Anisodamine The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Anisodamine.
Bucindolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Bucindolol.
Esatenolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Esatenolol.
Cloranolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Cloranolol.
Mepindolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Mepindolol.
Epanolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Epanolol.
Tertatolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Tertatolol.
Landiolol The risk or severity of hypersensitivity reaction can be increased when Patent Blue is combined with Landiolol.
Vasopressin The risk or severity of hypotension can be increased when Patent Blue is combined with Vasopressin.
Felypressin The risk or severity of hypotension can be increased when Patent Blue is combined with Felypressin.
Midodrine The risk or severity of hypotension can be increased when Patent Blue is combined with Midodrine.
Methysergide The risk or severity of hypotension can be increased when Patent Blue is combined with Methysergide.
Dihydroergotamine The risk or severity of hypotension can be increased when Patent Blue is combined with Dihydroergotamine.
Norepinephrine The risk or severity of hypotension can be increased when Patent Blue is combined with Norepinephrine.
Phenylephrine The risk or severity of hypotension can be increased when Patent Blue is combined with Phenylephrine.
Phenylpropanolamine The risk or severity of hypotension can be increased when Patent Blue is combined with Phenylpropanolamine.
Metaraminol The risk or severity of hypotension can be increased when Patent Blue is combined with Metaraminol.
Epinephrine The risk or severity of hypotension can be increased when Patent Blue is combined with Epinephrine.
Sumatriptan The risk or severity of hypotension can be increased when Patent Blue is combined with Sumatriptan.
Ergotamine The risk or severity of hypotension can be increased when Patent Blue is combined with Ergotamine.
Methoxamine The risk or severity of hypotension can be increased when Patent Blue is combined with Methoxamine.
Pseudoephedrine The risk or severity of hypotension can be increased when Patent Blue is combined with Pseudoephedrine.
Cocaine The risk or severity of hypotension can be increased when Patent Blue is combined with Cocaine.
Oxymetazoline The risk or severity of hypotension can be increased when Patent Blue is combined with Oxymetazoline.
Naratriptan The risk or severity of hypotension can be increased when Patent Blue is combined with Naratriptan.
Ephedrine The risk or severity of hypotension can be increased when Patent Blue is combined with Ephedrine.
Mephentermine The risk or severity of hypotension can be increased when Patent Blue is combined with Mephentermine.
S-Ethylisothiourea The risk or severity of hypotension can be increased when Patent Blue is combined with S-Ethylisothiourea.
Terlipressin The risk or severity of hypotension can be increased when Patent Blue is combined with Terlipressin.
Calyculin A The risk or severity of hypotension can be increased when Patent Blue is combined with Calyculin A.
Levonordefrin The risk or severity of hypotension can be increased when Patent Blue is combined with Levonordefrin.
Naphazoline The risk or severity of hypotension can be increased when Patent Blue is combined with Naphazoline.
Tetryzoline The risk or severity of hypotension can be increased when Patent Blue is combined with Tetryzoline.
Etilefrine The risk or severity of hypotension can be increased when Patent Blue is combined with Etilefrine.
Cirazoline The risk or severity of hypotension can be increased when Patent Blue is combined with Cirazoline.
Synephrine The risk or severity of hypotension can be increased when Patent Blue is combined with Synephrine.
Racepinephrine The risk or severity of hypotension can be increased when Patent Blue is combined with Racepinephrine.
Angiotensin II The risk or severity of hypotension can be increased when Patent Blue is combined with Angiotensin II.
Octopamine The risk or severity of hypotension can be increased when Patent Blue is combined with Octopamine.
Adrenalone The risk or severity of hypotension can be increased when Patent Blue is combined with Adrenalone.
Ornipressin The risk or severity of hypotension can be increased when Patent Blue is combined with Ornipressin.
Angiotensinamide The risk or severity of hypotension can be increased when Patent Blue is combined with Angiotensinamide.
Lypressin The risk or severity of hypotension can be increased when Patent Blue is combined with Lypressin.
Sildenafil The therapeutic efficacy of Sildenafil can be decreased when used in combination with Patent Blue.
Citalopram The therapeutic efficacy of Citalopram can be decreased when used in combination with Patent Blue.
Pregabalin The therapeutic efficacy of Pregabalin can be decreased when used in combination with Patent Blue.
Milrinone The therapeutic efficacy of Milrinone can be decreased when used in combination with Patent Blue.
Ranolazine The therapeutic efficacy of Ranolazine can be decreased when used in combination with Patent Blue.
Isradipine The therapeutic efficacy of Isradipine can be decreased when used in combination with Patent Blue.
Theophylline The therapeutic efficacy of Theophylline can be decreased when used in combination with Patent Blue.
Nitroprusside The therapeutic efficacy of Nitroprusside can be decreased when used in combination with Patent Blue.
Diltiazem The therapeutic efficacy of Diltiazem can be decreased when used in combination with Patent Blue.
Minoxidil The therapeutic efficacy of Minoxidil can be decreased when used in combination with Patent Blue.
Treprostinil The therapeutic efficacy of Treprostinil can be decreased when used in combination with Patent Blue.
Amlodipine The therapeutic efficacy of Amlodipine can be decreased when used in combination with Patent Blue.
Nimodipine The therapeutic efficacy of Nimodipine can be decreased when used in combination with Patent Blue.
Nisoldipine The therapeutic efficacy of Nisoldipine can be decreased when used in combination with Patent Blue.
Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Patent Blue.
Nitric Oxide The therapeutic efficacy of Nitric Oxide can be decreased when used in combination with Patent Blue.
Prazosin The therapeutic efficacy of Prazosin can be decreased when used in combination with Patent Blue.
Fluoxetine The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Patent Blue.
Lercanidipine The therapeutic efficacy of Lercanidipine can be decreased when used in combination with Patent Blue.
Bosentan The therapeutic efficacy of Bosentan can be decreased when used in combination with Patent Blue.
Cinnarizine The therapeutic efficacy of Cinnarizine can be decreased when used in combination with Patent Blue.
Nicardipine The therapeutic efficacy of Nicardipine can be decreased when used in combination with Patent Blue.
Niacin The therapeutic efficacy of Niacin can be decreased when used in combination with Patent Blue.
Adenosine The therapeutic efficacy of Adenosine can be decreased when used in combination with Patent Blue.
Dyphylline The therapeutic efficacy of Dyphylline can be decreased when used in combination with Patent Blue.
Magnesium sulfate The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Patent Blue.
Verapamil The therapeutic efficacy of Verapamil can be decreased when used in combination with Patent Blue.
Phentolamine The therapeutic efficacy of Phentolamine can be decreased when used in combination with Patent Blue.

Target Protein

Albumin ALB

Referensi & Sumber

Artikel (PubMed)
  • PMID: 26670899
    Iqbal FM, Basit A, Salem F, Vidya R: Feeling blue, going green and finding other attractive alternatives: a case of biphasic anaphylaxis to patent blue and a literature review of alternative sentinel node localisation methods. BMJ Case Rep. 2015 Dec 15;2015. pii: bcr-2015-213107. doi: 10.1136/bcr-2015-213107.
  • PMID: 23325942
    Tripathy S, Nair PV: Adverse drug reaction, patent blue V dye and anaesthesia. Indian J Anaesth. 2012 Nov;56(6):563-6. doi: 10.4103/0019-5049.104576.
  • PMID: 24415970
    Gumus M, Gumus H, Jones SE, Jones PA, Sever AR, Weeks J: How long will I be blue? Prolonged skin staining following sentinel lymph node biopsy using intradermal patent blue dye. Breast Care (Basel). 2013 Jun;8(3):199-202. doi: 10.1159/000352092.
  • PMID: 23203181
    Joshi M, Hart M, Ahmed F, McPherson S: Adverse reaction; patent blue turning patient blue. BMJ Case Rep. 2012 Nov 30;2012. pii: bcr-2012-007339. doi: 10.1136/bcr-2012-007339.

Contoh Produk & Brand

Produk: 1 • International brands: 0
Produk
  • Patent Blue Sodium Injection
    Solution • 50 mg / 2 mL • Intravenous; Subcutaneous • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul